The world’s first plant-derived covid-19 vaccine A novel vaccine formulation to combat the virus, from a unit of Mitsubishi Chemical Holdings Corp and Philip Morris International, was approved for use in Canada.
The vaccine named Covifenz was jointly developed by Medicago Inc. , a biopharma company owned by Mitsubishi Chemical and Philip Morris and based in Quebec City and GlaxoSmithKline plc.
Here are 10 things to know about the Covifenz vaccine:
It is the first authorized COVID-19 vaccine developed by a Canadian company, and the first that uses plant-based protein technology.
Medicago’s Covifenz is authorized as a two-dose dose of 2.75 micrograms per dose, to be administered at 21-day intervals.
In clinical trials, the vaccine was found to be 71 percent effective against symptomatic infection and 100% effective against severe disease caused by COVID-19.
Covifenz vaccine data suggest efficacy against several variants, including delta.
Clinical trials with Covifenz showed efficacy against delta and gamma variants, and data also suggested efficacy against alpha, lambda and mu variants.
Health Canada and the Public Health Agency of Canada will continue to closely monitor the safety of this vaccine, and will take action if any safety concerns are identified.
It is the first authorized COVID-19 vaccine developed by a Canadian company, and the first that uses plant-based protein technology.
possible side effects:
After getting the vaccine, it is common to have temporary side effects. These can last from a few hours to a few days after vaccination.
This is the body’s natural response, as it is working hard to build protection from illness that includes chills, fatigue, joint pain, headache, mild fever, muscle aches, nasal congestion, sore throat, cough, Includes nausea, diarrhea.
The dosing schedule approved by Health Canada is to deliver 2 doses 21 days apart based on evidence from clinical trials. Each dose contains 3.75 µg of SARS-CoV-2 spike (S) protein and 0.25 ml of AS03 adjuvant.
medicinal material
Plant-based virus-like particles (VLPs) of SARS-CoV-2 spike protein (original strain) AS03 adjuvant (manufactured by GlaxoSmithKline):
dl-alpha-tocopherol
squalene
polysorbate 80
phosphate resistant salts
Never miss a story! Stay connected and informed with Mint.
download
Our App Now!!
,